<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ZIDOVUDINE (AZIDOTHYMIDINE, AZT) </span><br/>(zye-doe'vyoo-deen)<br/><span class="topboxtradename">Retrovir<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Lamivudine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>300 mg tablets; 100 mg capsules; 50 mg/5 mL syrup; 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Analog of thymidine (a major nucleoside in DNA). On entering host cell, zidovudine is converted to a triphosphate (the active
         form) by endogenous thymidine kinase and other cellular enzymes. Appears to act by being incorporated into growing DNA chains
         by viral reverse transcriptase, thereby terminating viral replication.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Zidovudine has antiviral action against HIV (human immunodeficiency virus), the causative agent of AIDS (acquired immune deficiency
         syndrome), LAV (lymphadenopathy-associated virus), and ARV (AIDS-associated retrovirus).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Patients who are HIV positive and have a CD4 count <img src="../images/special/lesserorequal.gif"/>500/mm<sup>3</sup>, asymptomatic HIV infection, early and late symptomatic HIV disease, prevention of perinatal transfer of HIV during pregnancy.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Pediatric patients, postexposure chemoprophylaxis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Life-threatening allergic reactions to any of the components of the drug. Safe use during pregnancy (category C), lactation,
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired renal or hepatic function, bone marrow depression.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Symptomatic HIV Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg q4h (1200 mg/d), after 1 mo may reduce to 100 mg q4h (600 mg/d) <span class="rdroute">IV</span> 12 mg/kg q4h (1200 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span>
<i>3 mo13 y</i>, 100180 mg/m<sup>2</sup> q6h<br/><br/><span class="indicationtitle">Asymptomatic HIV Infection, Post-Exposure Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg q4h while awake, 5 times/d<br/><br/><span class="indicationtitle">Prevention of Maternal-Fetal Transmission</span><br/><span class="rdage">Neonate:</span> <span class="rdroute">PO</span> 2 mg/kg q6h for 6 wk beginning within 12 h after birth<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not expose capsules and syrup to light during drug preparation.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Withdraw required dose from vial and dilute with D5W to a concentration not to exceed 4 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span> Give calculated dose at a constant rate over 60 min; avoid rapid infusion.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°25° C (59°77° F) and protected from light unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Fever,</span> dyspnea, <span class="speceff-common">malaise,</span> weakness, <span class="speceff-common">myalgia,</span> myopathy. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> insomnia, dizziness, paresthesias, mild confusion, anxiety, restlessness, agitation. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> diarrhea, <span class="speceff-common">vomiting, anorexia,</span> GI pain. <span class="typehead">Hematologic:</span>
<span class="speceff-both">Bone marrow depression, granulocytopenia, anemia.</span>
<span class="typehead">Respiratory:</span>
<span class="speceff-common">Cough, wheezing</span>. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash,</span> itching, diaphoresis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Acetaminophen ganciclovir,</b>
<b>interferon-alfa</b> may enhance bone marrow suppression; <b>Atovaquone,</b>
<b>amphotericin B,</b>
<b>aspirin,</b>
<b>dapsone,</b>
<b>doxorubicin,</b>
<b>fluconazole,</b>
<b>flucytosine,</b>
<b>indomethacin,</b>
<b>interferon alfa,</b>
<b>methadone,</b>
<b>pentamidine,</b>
<b>vincristine, valproic acid</b> may increase risk of AZT toxicity; <b>probenecid</b> will decrease AZT elimination, resulting in increased serum levels and thus toxicity. <b>Nelfinavir,</b>
<b>rifampin,</b>
<b>ritonavir</b> may decrease zidovodine (AZT) concentrations; other <span class="classification">antiretroviral agents</span> may cause lactic acidosis and severe hepatomegaly with steatosis; <b>stavudine,</b>
<b>doxorubicin</b> may antagonize AZT effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 6070% reaches systemic circulation (first-pass metabolism). <span class="typehead">Peak:</span> 0.51.5 h.  <span class="typehead">Distribution:</span> Crosses bloodbrain barrier and placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 6395% excreted in urine. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Evaluate patient at least weekly during the first month of therapy.</li>
<li>Lab tests: Baseline and frequent (at least q2wk) blood counts, CD4 (T<sub>4</sub>) lymphocyte count, Hgb, and granulocyte count to detect hematologic toxicity.
         </li>
<li>Myelosuppression results in anemia, which commonly occurs after 46 wk of therapy, and granulocytopenia in 68 wk.
            Frequently, both respond to dosage adjustment. Significant anemia (Hgb 25% of baseline value),
            or granulocyte count 3 (or reduction &gt;50% of baseline) may require temporary interruption of therapy and transfusions.
         </li>
<li>Monitor for common adverse effects, especially severe headache, nausea, insomnia, and myalgia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician promptly if health status worsens or any unusual symptoms develop.</li>
<li>Understand that this drug is not a cure for HIV infection; you will continue to be at risk for opportunistic infections.</li>
<li>Do not share drug with others; take drug exactly as prescribed.</li>
<li>Drug does <small>NOT</small> reduce the risk of transmission of HIV infection through body fluids.
         </li>
<li>Do not breast feed while taking this drug; it is not known if the drug is secreted in human milk.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>